The recall includes 80 milligrams per 8-milliliter multi-dose vials and 160 milligrams per 16-milliliter multi-dose vials of docetaxel injection. The therapy is indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma, and head and neck squamous cell carcinoma.
If there’s a particulate matter in an injectable drug, patients face the risk of serious adverse events, the FDA said.
The particulates were detected in the product’s stopper, and to date, Sagent has not received any adverse event reports.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.